[Market Highlight] Orym Therapeutics Hits Record High on KRW 145 Billion CPS Investment

Orym Therapeutics is showing strong performance in early trading.

As of 9:05 a.m. on December 19, Orym Therapeutics was trading at 97,300 won, up 11.45% (10,000 won) from the previous day. During the session, the price rose to 98,600 won, setting a new 52-week high. The news that the company secured a convertible preferred stock (CPS) investment worth 145 billion won appears to have boosted investor sentiment.

This CPS investment round, which included existing investor KB Investment as well as several new investors such as Wise Asset Management and Korea Investment Partners, was pursued to further develop existing pipelines like ORM-1153, develop new payload classes, and advance the DAC platform.

Lee Seungjoo, CEO of Orym Therapeutics, stated, "This investment will provide a crucial foundation for advancing our key pipelines that are about to enter the clinical stage, developing new payloads, and establishing a platform capable of creating differentiated new drug candidates in a variety of disease areas beyond oncology."

This content was produced with the assistance of AI translation services.